RPTXRepare Therapeutics Inc
Mkt Cap
$82.05MVolume
192,271.0052W High
$4.0752W Low
$0.89PE Ratio
-0.74RPTX Fundamentals
Price
$1.93Prev Close
$1.91Open
$1.8850D MA
$1.73Beta
1.10Avg. Volume
87,645.38EPS (Annual)
-$2.00P/B
0.74Rev/Employee
$414,550.39Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy...
Business Wire·10d ago
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
Repare Therapeutics (RPTX) delivered earnings and revenue surprises of +30.36% and -95.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In
The deal builds on an existing collaboration around lunresertib and hands development control to Debiopharm, allowing Repare to focus on its Phase 1 trials for RP-1664 and RP-3467.
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re-prioritization of its...
Business Wire·10mo ago
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...
PR Newswire·10mo ago
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive data from its MYTHIC Phase 1 gynecologic expansion...
Business Wire·10mo ago
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the...
Business Wire·11mo ago
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been...
Business Wire·1y ago
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2024...
Business Wire·1y ago
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data highlighting the benefits of its individualized...
Business Wire·1y ago